Injection that prevents migraine is approved by ANVISA

The first drug made exclusively for the prevention of migraine received the name of Pasurta and was approved by the National Health Surveillance Agency (ANVISA).

Treatment is done through a monthly injection that blocks CGRP (protein related to migraine attacks).

According to research, the new drug reduces headaches caused by this condition by up to 50% .

Pasurta has been legalized in the United States since May 2018. According to the laboratory responsible for the manufacture of the drug, Novartis, about 175 thousand people already use the injection.

After approval, the estimate is that the drug will begin to be sold in Brazil by the middle of 2019.

Migraine affects thousands of people

According to the World Health Organization (WHO), 324 million people suffer from migraine worldwide. Of this total, 25% have headaches for more than 3 days a month.

Women have a 43% chance of developing the disease throughout their lives and men have an 18% chance.

Migraine is a brain condition that causes severe headaches that may be accompanied by tiredness , nausea, nausea, intolerance to light (photophobia) and sound (phonophobia).

This is a chronic disease, that is, it can last a lifetime. People with a family history of migraine are more likely to develop the disease throughout their lives.

Migraine can be made worse by the consumption of some foods (such as sausages, alcoholic beverages, chocolate, coffee). Lack of regular sleep, excessive sun exposure and smoking can also facilitate the onset of the disease or worsen it.

The diagnosis is made by medical evaluation based on the patient’s symptoms. In some cases, tests are needed to see if there is a relationship between migraine and other conditions.